
A new study involving over 486,000 adults aimed to assess the risk of oesophageal adenocarcinoma in patients with non-erosive gastro-oesophageal reflux disease (GERD) compared to the general population. The research revealed that among the 285,811 patients with non-erosive GERD, only 228 developed oesophageal adenocarcinoma during a follow-up period of up to 31 years. The incidence rate for this group was 11.0/100,000 person-years, similar to the general population. Consequently, the study suggests that patients with non-erosive GERD do not require additional endoscopic monitoring for oesophageal adenocarcinoma. In contrast, patients with erosive GERD had a higher risk of developing the cancer.
Like
Save
Share